NCT04706286

Clinical Trial to Investigate the Pharmacokinetics and Safety of CKD-393

A Randomized, Open-label, Single-dose, Two-way Crossover Clinical Trial to Investigate the Pharmacokinetics and Safety of CKD-393 and Co-administration of CKD-501, D759 and D150 Under Fed Condition in Healthy Adults

• Status: Unknown
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 26 (estimated)
• Sponsor: Chong Kun Dang Pharmaceutical · Industry
• Sex: All
• Age: 19 Years – 55 Years
• Healthy volunteers: Accepted

Summary

A Clinical Trial to evaluate the Pharmacokinetics and safety of CKD-393 0.5/100/1000 mg under fed condition

Detailed description

A Phase 1 Clinical Trial to evaluate the safety and pharmacokinetics in healthy adult volunteers after administration of CKD-393 0.5/100/1000 mg under fed condition.

Conditions

• T2DM (Type 2 Diabetes Mellitus)

Interventions

Type	Name	Description
DRUG	CKD-501, D759, D150	CKD-501 0.5 mg 1T, D759 100 mg 1T and D150 1000 mg 1T, single oral administration under fed condition
DRUG	CKD-393 0.5/100/1000 mg	CKD-393 0.5/100/1000 mg 1T, single oral administration under fed condition

Timeline

• Start date: 2021-02-18
• Primary completion: 2021-03-29
• Completion: 2021-04-05
• First posted: 2021-01-12
• Last updated: 2021-01-12

Locations

1 site across 1 country: South Korea